Howard J Huang, Kenneth Schechtman, Medhat Askar, Cory Bernadt, Brigitte Mitter, Peter Dore, Ahmad Goodarzi, Simon Yau, J Georges Youssef, Chad A Witt, Derek E Byers, Rodrigo Vazquez-Guillamet, Laura Halverson, Ruben Nava, Varun Puri, Daniel Kreisel, Andrew E Gelman, Ramsey R Hachem
BACKGROUND: Chronic lung allograft dysfunction (CLAD) is the leading cause of death beyond the first year after lung transplantation. The development of donor-specific antibodies (DSA) is a recognized risk factor for CLAD. Based on experience in kidney transplantation, we hypothesized that belatacept, a selective T-cell costimulatory blocker, would reduce the incidence of DSA after lung transplantation, which may ameliorate the risk of CLAD. METHODS: We conducted a pilot randomized controlled trial (RCT) at 2 sites to assess the feasibility and inform the design of a large-scale RCT...
October 30, 2023: Transplantation